IN8bio to Present at November Investor Conferences

Rhea-AI Summary

IN8bio, a clinical-stage biopharmaceutical company, has announced that CEO William Ho will present at two investor conferences in November 2022. He will participate in the BioFuture 2022 on November 8, presenting at 9:30 a.m. ET and again at 2:30 p.m. ET. Additionally, he will present at the Stifel 2022 Healthcare Conference on November 15 at 10:20 a.m. ET. The Stifel presentation will be available live and as a replay on the company's website. IN8bio is focused on developing gamma-delta T cell therapies for solid and liquid tumors.

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, CEO and co-founder, will be presenting at two investor conferences in November.

• BioFuture 2022, November 8, 2022
  • Next-Generation Cancer Therapeutics: Multiple Approaches Showing Promise panel at 9:30 a.m. ET
  • Corporate presentation at 2:30 p.m. ET
    
    
• Stifel 2022 Healthcare Conference, November 15, 2022
  • Corporate presentation at 10:20 a.m. ET

The Stifel presentation will be available live and as a replay on IN8bio’s website at https://bit.ly/3F1WEaQ.

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.

Company Contact:
IN8bio, Inc.
Patrick McCall
+ 1 646.600.6GDT (6438)
info@IN8bio.com

Investors & Media Contact:
Argot Partners
IN8bio@argotpartners.com

FAQ

What are the dates and times of IN8bio's investor conferences?

IN8bio will present at the BioFuture 2022 on November 8, 2022, at 9:30 a.m. ET and 2:30 p.m. ET, and at the Stifel 2022 Healthcare Conference on November 15, 2022, at 10:20 a.m. ET.

Where can I watch the Stifel presentation for IN8bio?

The Stifel presentation for IN8bio will be available live and as a replay on the company's website at https://bit.ly/3F1WEaQ.

What is the primary focus of IN8bio's research?

IN8bio focuses on the discovery and development of gamma-delta T cell therapies for treating solid and liquid tumors.

What are the lead product candidates being developed by IN8bio?

IN8bio's lead product candidates include INB-200 for glioblastoma and INB-100 for leukemia patients undergoing stem cell transplantation.

What is the unique approach IN8bio uses for its therapies?

IN8bio utilizes the DeltEx platform, which employs allogeneic, autologous, iPSC, and genetically modified approaches to develop cell therapies.